S. Hartman

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

S. Eckhardt, J. Tentler, T. Pitts, 2020, BMC cancer.

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

S. Eckhardt, J. Tentler, T. Pitts, 2020, Cancers.

WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma

J. Tentler, T. Pitts, J. Diamond, 2021, Frontiers in Oncology.

Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models

Matthew S. Lewis, Kimberly R. Jordan, S. Eckhardt, 2022, Frontiers in Oncology.

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

T. Pitts, J. Diamond, W. Messersmith, 2022, BMC Cancer.

Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes

Matthew S. Lewis, S. Eckhardt, T. Pitts, 2021, Frontiers in Immunology.

First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer

Jihye Kim, A. Tan, J. Tentler, 2019, Molecular Cancer Therapeutics.

Preclinical development of the class I selective histone deacetylase inhibitor OKI-179 for the treatment of solid tumors.

Michael K. Wendt, Xuedong Liu, S. Eckhardt, 2021, Molecular cancer therapeutics.